Hématologie
Prior to this new therapy standard from medac for these fragile patient groups, there had been no real progress in conditioning therapy ahead of an allogeneic stem cell transplant for years. This example illustrates how we at medac identify and address clinical needs in a targeted manner in order to improve the lives and treatment options for patients.
Today, medac has profound expertise in haematology and a very broad portfolio around our focus products, with a reputation as an exceptionally reliable partner that offers the highest level of service. Through the years of research and development, medac has built up an extensive network of specialists, opinion leaders, and therapists, who form the foundation for further research and the expansion of therapeutic areas based on the identified clinical need. Furthermore, not only do we support clinical trials and other research to expand the use of our products in haematology, but we also support education and knowledge transfer to the medical field. This is how we ensure that even more patients can benefit from our products.
By manufacturing according to European quality standards, we can guarantee that our products used worldwide are of high quality and stability. The reliable supply also plays a key role in the development of new products. Our efforts to continuously optimise production processes have ultimately led to the development of products, that address patients’ as well as clinical needs in a targeted manner.
Another clinical need that we identified and addressed at medac is the steroid refractory acute graft-versus-host disease (GvHD) in patients following allogeneic stem cell transplantation. In GvHD, the donor's immune cells recognise the recipient's cells as foreign and attack them. Currently, medac is developing a cell therapy for this life-threatening disease. An exemption permit from the responsible German authority allows medac to distribute this product in Germany and underlines our innovative mindset.
